Novartis (NVS)
(Delayed Data from NYSE)
$99.68 USD
-0.85 (-0.85%)
Updated May 28, 2024 04:00 PM ET
After-Market: $99.75 +0.07 (0.07%) 6:08 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
Novartis AG [NVS]
Reports for Purchase
Showing records 81 - 100 ( 475 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended January 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 122122
Provider: Stock Traders Daily
Analyst: Research Department